Home › Funds › Lynx1 Capital Management LP › TRDA
Lynx1 Capital Management LP position in TRDA
ENTRADA THERAPEUTICS INC · Health Care
Lynx1 Capital Management LP reported holding 178,606 shares of TRDA (ENTRADA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$1.3M, representing 0.15% of its reported portfolio and ranking #13 among its reported holdings. Lynx1 Capital Management LP has disclosed TRDA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lynx1 Capital Management LP's TRDA position evolved
Lynx1 Capital Management LP first disclosed a stake in TRDA in Q4 2025 at 51,689 shares (US$531K). The position peaked in Q1 2026 at 211,689 shares, worth US$2.7M. Across 3 filings, Lynx1 Capital Management LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 178,606 shares valued at US$1.3M — a reduction of -33,083 shares quarter over quarter.. Notable position changes include a 310% increase in Q1 2026 (shares fell 42% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 51.69K | $531.36K | New |
| Q1 2026 | 211.69K | $2.67M | Add |
| Q2 2026 | 178.61K | $1.31M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRDA and 13F data
TRDA (ENTRADA THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in TRDA — the largest reported positions include BAKER BROS. ADVISORS LP (US$37.3M), 5AM Venture Management, LLC (US$29.9M), Merck & Co., Inc. (US$12.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRDA
- BAKER BROS. ADVISORS LP 5.07M sh · $37.34M · Q2 2026
- 5AM Venture Management, LLC 4.06M sh · $29.85M · Q2 2026
- Merck & Co., Inc. 1.74M sh · $12.80M · Q2 2026
- MPM BioImpact LLC 1.25M sh · $9.22M · Q2 2026
- TCG Crossover Management, LLC 1.06M sh · $7.80M · Q2 2026
- StepStone Group LP 761.28K sh · $5.60M · Q2 2026
More on Lynx1 Capital Management LP
FAQ
How long has Lynx1 Capital Management LP held TRDA?
Lynx1 Capital Management LP has disclosed TRDA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Lynx1 Capital Management LP's current position in TRDA?
As of Q2 2026, Lynx1 Capital Management LP holds 178.61K shares of TRDA (ENTRADA THERAPEUTICS INC), valued at $1.31M, representing 0.15% of its reported portfolio and ranking #13.
Has Lynx1 Capital Management LP been buying or selling TRDA?
In the latest 13F filing (Q2 2026), Lynx1 Capital Management LP reduced its position in TRDA. The position peaked in Q1 2026 at 211.69K shares.
Which other funds hold TRDA?
Other major institutional holders of TRDA include BAKER BROS. ADVISORS LP, 5AM Venture Management, LLC, Merck & Co., Inc., among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.